Condition
Severe Spasticity
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 3 (1)
P 4 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT00773019CompletedPrimary
SynchroMed II Post-Approval Study
NCT01520545Phase 3CompletedPrimary
Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump
NCT01032239Phase 4CompletedPrimary
SISTERS: Spasticity In Stroke Study - Randomized Study
Showing all 3 trials